C00-C97
Conditions
Interventions
Group 1: In our Molecular Tumor Board (MTB), the medical history and previous medical findings of the study participants are presented in an interdisciplinary conference attended by medical and scient
Sponsors
Universitätsklinikum Würzburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Recommendation in the organ tumor board for a discussion in the molecular tumor board - Guideline-based and evidence-based therapy already exhausted or to be exhausted in the foreseeable future - Molecular genetic findings with unclear relevance - Results of routine diagnostics not sufficiently informative
Exclusion criteria
Exclusion criteria: - Lack of ability to give consent or informed consent for registry study. - Lack of consent for tissue and data release and lack of consent for genetic testing/panel diagnostics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary aim of the study is to provide insights into the following points by means of a systematic and structured recording and evaluation of MTB cases in Würzburg: - Characteristics of the patients* presented - Frequency/type of diagnostic methods used - Frequency/type/relevance of molecular-genetic alterations detected - frequency/type of therapy recommendations and their implementation - further course of treatment of the patients | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary aim of the study is to generate initial evidence for the following questions: - Which patient groups benefit from molecular genetic testing? - Which biomarkers are relevant and targetable? - How effective are the recommended therapies? | — |
Countries
Germany
Contacts
Public ContactMichaela Metz
Universitätsklinikum Würzburg Comprehensive Cancer Center Mainfranken
Outcome results
None listed